Articles related to OBESITY/WEIGHT MANAGEMENT

The approval was based on data from the randomized, double-blinded, parallel-group phase 3b STEP UP trial, which enrolled 1407 adults aged 18 years and older with a body mass index of at least 30kg/m2, without diabetes.

“It gives clinicians objective clinical evidence guidance as to the risks and benefits of napping and catching up on sleep during weekends.” — Kaushik Govindaraju, DO, Medical Offices of Manhattan

The Wegovy tablet is the first oral GLP-1 receptor agonist indicated for weight loss and cardiovascular risk reduction in eligible adults.

If approved, retatrutide will be the first in a new class of medications combining GIP, GLP-1, and glucagon receptor agonism in a single once-weekly injection.

Early treatment phases may transiently promote immune activation, whereas sustained therapy, by reducing BMI and lowering systemic inflammation, may mitigate this effect.

“These results demonstrate the uneven distribution of obesity and severe obesity across youths in the United States and underscore the need for ongoing treatment, prevention, and public health interventions.” — Dr. William J. Heerman, Vanderbilt University Medical Center